Two decades of Huntington disease testing: patient's demographics and reproductive choices.

Krukenberg RC, Koller DL, Weaver DD, Dickerson JN, Quaid KA.

J Genet Couns. 2013 Oct;22(5):643-53. doi: 10.1007/s10897-013-9596-0.

Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.

Xiao G, Fan Q, Wang X, Zhou B.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14995-5000. doi: 10.1073/pnas.1308535110.

Rhes, a key element of selective neuronal vulnerability in Huntington's disease: a striatal-specific license to kill during energy metabolism failure.

Ghiglieri V, Calabresi P.

Mov Disord. 2013 Jun;28(6):735. doi: 10.1002/mds.25476. No abstract available.

A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.

Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Déglon N, Beal MF, Brouillet E.

Hum Mol Genet. 2013 Oct 1;22(19):3869-82. doi: 10.1093/hmg/ddt242.

Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models.

Tauffenberger A, Chitramuthu BP, Bateman A, Bennett HP, Parker JA.

Hum Mol Genet. 2013 Feb 15;22(4):782-94. doi: 10.1093/hmg/dds485.

Preliminary analysis of Huntington's Disease in South Korea.

Shin CW, Choi YJ, Kim M, Jeon BS.

J Huntingtons Dis. 2013;2(1):83-7. doi: 10.3233/JHD-120040.

The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.

Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR.

Eur J Neurol. 2013 Sep;20(9):1325-9. doi: 10.1111/ene.12053.

Ophthalmologic involvement in Japanese siblings with chorea-acanthocytosis caused by a novel chorein mutation.

Ogawa I, Saigoh K, Hirano M, Mtsui Y, Sugioka K, Takahashi J, Shimomura Y, Tani Y, Nakamura Y, Kusunoki S.

Parkinsonism Relat Disord. 2013 Oct;19(10):913-5. doi: 10.1016/j.parkreldis.2013.05.012. No abstract available.

Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS; PREDICT-HD study group..

Neurobiol Dis. 2013 Jul;55:37-43. doi: 10.1016/j.nbd.2013.03.013.

A critical evaluation of inflammatory markers in Huntington's Disease plasma.

Silajdžić E, Rezeli M, Végvári Á, Lahiri N, Andre R, Magnusson-Lind A, Nambron R, Kalliolia E, Marko-Varga G, Warner TT, Laurell T, Tabrizi SJ, Björkqvist M.

J Huntingtons Dis. 2013;2(1):125-34. doi: 10.3233/JHD-130049.

A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Du X, Pang TY, Hannan AJ.

Front Neurol. 2013 Jul 9;4:81. doi: 10.3389/fneur.2013.00081.

Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.

Kumar A, Sharma N, Mishra J, Kalonia H.

Eur J Pharmacol. 2013 Jun 5;709(1-3):1-12. doi: 10.1016/j.ejphar.2013.03.042.

Huntington disease-like 2 (HDL2) in Venezuela: frequency and ethnic origin.

Paradisi I, Ikonomu V, Arias S.

J Hum Genet. 2013 Jan;58(1):3-6. doi: 10.1038/jhg.2012.111.

Atg4b-dependent autophagic flux alleviates Huntington's disease progression.

Proenca CC, Stoehr N, Bernhard M, Seger S, Genoud C, Roscic A, Paganetti P, Liu S, Murphy LO, Kuhn R, Bouwmeester T, Galimberti I.

PLoS One. 2013 Jul 8;8(7):e68357. doi: 10.1371/journal.pone.0068357.

The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease.

Van Liew C, Gluhm S, Goldstein J, Cronan TA, Corey-Bloom J.

Psychiatry. 2013 Winter;76(4):323-35. doi: 10.1521/psyc.2013.76.4.323.